Integration of epidemiology, immunobiology, and translational research for brain tumors

Annals of the New York Academy of Sciences

Volumn 1284, Issue 1, 2013, Pages 17-23

  Okada, Hideho ^a   Scheurer, Michael E ^b   Sarkar, Saumendra N ^a   Bondy, Melissa L ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Glioma; Interferon; Nonsteroidal antiinflammatory drugs; Single nucleotide polymorphism

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; BONE MARROW CELL; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER RESEARCH; GENE; GLIOMA; IFNA8 GENE; IMMUNOBIOLOGY; IMMUNOSURVEILLANCE; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84877328940     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12115     Document Type: Article

References (65)

1. CBTRUS. 2012. Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2008, Central Brain Tumor Registry of the United States.
2. Karim, A.B., B. Maat, R. Hatlevoll, et al. 1996. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36: 549-556.
3. van den Bent, M.J., D. Afra, W.O. De, et al. 2005. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366: 985-990.
4. Karim, A.B., D. Afra, P. Cornu, et al. 2002. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52: 316-324.
5. Shaw, E., R. Arusell, B. Scheithauer, et al. 2002. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J. Clin. Oncol. 20: 2267-2276.
6. Shaw, E.G., B. Berkey, S.W. Coons, et al. 2006. Radiation Therapy Oncology Group Protocol 9802: radiation therapy alone versus RT + PCV chemotherapy in adult low-grade glioma. Neuro Oncol. 8: 489.
7. Shaw, E.G., B. Berkey, S.W. Coons, et al. 2006. Update of an RTOG prospective study of observation in completely resected adult low-grade glioma. Neuro Oncol. 8: 452.
8. Papagikos, M.A., E.G. Shaw, & V.W. Stieber 2005. Lessons learned from randomised clinical trials in adult low-grade glioma. Lancet Oncol. 6: 240-244.
9. Pignatti, F., B.M. van den, D. Curran, et al. 2002. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 20: 2076-2084.
10. Shaw, E.G., B. Berkey, S.W. Coons, et al. 2008. Recurrence following neurosurgeon-determined gross total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J. Neurosurg. 109: 835-841.
11. Brown, P.D., E.G. Shaw, L.L. Gunderson, et al. 2006. Low-Grade Gliomas, Clinical Radiation Oncology. 493-514. Philadelphia, PA: Churchill-Livingstone.
12. Sanai, N., S. Chang & M.S. Berger 2011. Low-grade gliomas in adults. J. Neurosurg. 115: 948-965.
13. Fisher, J.L., J.A. Schwartzbaum, M. Wrensch, et al. 2007. Epidemiology of brain tumors. Neurol. Clin. 25: 867-890.
14. Schwartzbaum, J.A., K. Huang, S. Lawler, et al. 2010. Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol. 12: 320-327.
15. Schwartzbaum, J.A., A. Ahlbom, S. Lonn, et al. 2007. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol. Biomarkers Prev. 16: 2448-2454.
16. Schwartzbaum, J., A. Ahlbom, B. Malmer, et al. 2005. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 65: 6459-6465.
17. Sivak-Sears, N.R., J.A. Schwartzbaum, R. Miike, et al. 2004. Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am. J. Epidemiol. 159: 1131-1139.
18. McCarthy, B.J., K.M. Rankin, K. Aldape, et al. 2011. Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol. 13: 242-250.
19. Schoemaker, M.J., A.J. Swerdlow, S.J. Hepworth, et al. 2006. History of allergies and risk of glioma in adults. Int. J. Cancer 119: 2165-2172.
20. Brenner, A.V., M.A. Butler, S.S. Wang, et al. 2007. Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma. Carcinogenesis 28: 2543-2547.
21. Brenner, A.V., M.S. Linet, H.A. Fine, et al. 2002. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int. J. Cancer 99: 252-259.
22. Linos, E., T. Raine, A. Alonso, et al. 2007. Atopy and risk of brain tumors: a meta-analysis. J. Natl. Cancer Instit. 99: 1544-1550.
23. Wiemels, J.L., J.K. Wiencke, K.T. Kelsey, et al. 2007. Allergy-related polymorphisms influence glioma status and serum IgE levels. Cancer Epidemiol. Biomarkers Prev. 16: 1229-1235.
24. Wiemels, J.L., J.K. Wiencke, J.D. Sison, et al. 2002. History of allergies among adults with glioma and controls. Int. J. Cancer 98: 609-615.
25. Wrensch, M., J.K. Wiencke, J. Wiemels, et al. 2006. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res. 66: 4531-4541.
26. Schwartzbaum, J.A., J.L. Fisher, K.D. Aldape, et al. 2006. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2: 494-503.
27. Scheurer, M.E., E. Amirian, Y. Cao, et al. 2008. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin. Cancer Res. 14: 6640-6646.
28. Scheurer, M.E., E.S. Amirian, S.L. Davlin, et al. 2011. Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int. J. Cancer 129: 2290-2296.
29. Scheurer, M.E., R. El-Zein, P.A. Thompson, et al. 2008. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol. Biomarkers Prev. 17: 1277-1281.
30. Fujita, M., M.E. Scheurer, S.A. Decker, et al. 2010. Role of type 1 IFNs in antiglioma immunosurveillance-using mouse studies to guide examination of novel prognostic markers in humans. Clin. Cancer Res. 16: 3409-3419.
31. Schwartzbaum, J.A., Y. Xiao, Y. Liu, et al. 2010. Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis 31: 1770-1777.
32. Amirian, E., Y. Liu, M.E. Scheurer, et al. 2010. Genetic variants in inflammation pathway genes and asthma in glioma susceptibility. Neuro Oncol. 12: 444-452.
33. Nakahara, N., I.F. Pollack, W.J. Storkus, et al. 2003. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther. 10: 549-558.
34. Tsugawa, T., N. Kuwashima, H. Sato ., et al. 2004. Sequential delivery of interferon-gene and DCs to intracranial gliomas promotes an effective anti-tumor response. Gene Ther. 11: 1551-1558.
35. Kuwashima, N., F. Nishimura, J. Eguchi, et al. 2005. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J. Immunol. 175: 2730-2740.
36. Nishimura, F., J.E. Dusak, J. Eguchi, et al. 2006. Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 66: 4478-4487.
37. Wiesner, S.M., S.A. Decker, J.D. Larson, et al. 2009. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res. 69: 431-439.
38. Kohanbash, G., E. Ishikawa, M. Fujita, et al. 2012. Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma. OncoImmunology 1: 487-492.
39. Fujita, M., G. Kohanbash, W. Fellows-Mayle, et al. 2011. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 71: 2664-2674.
40. Sinha, P., V.K. Clements, A.M. Fulton, et al. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507-4513.
41. Ochoa, A.C., A.H. Zea, C. Hernandez, et al. 2007. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13: 721s-726s.
42. Rodriguez, P.C. & A.C. Ochoa 2008. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222: 180-191.
43. Solomon, S.D., J. Wittes, P.V. Finn, et al. 2008. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104-2113.
44. Fidler, M.J., A. Argiris, J.D. Patel, et al. 2008. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin. Cancer Res. 14: 2088-2094.
45. Giglio, P. & V. Levin 2004. Cyclooxygenase-2 inhibitors in glioma therapy. Am. J. Ther. 11: 141-143.
46. Hau, P., L. Kunz-Schughart, U. Bogdahn, et al. 2007. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas-a phase II study. Oncology 73: 21-25.
47. Reardon, D.A., J.A. Quinn, J. Vredenburgh, et al. 2005. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103: 329-338.
48. Baumert, B.G. & R. Stupp 2008. Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy. Ann. Oncol. 19: vii217-vii222.
49. Ashby, L.S. & W.R. Shapiro 2004. Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr. Neurol. Neurosci. Rep. 4: 211-217.
50. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29: 330-336.
51. Zhu, X., B. Fallert-Junecko, M. Fujita, et al. 2010. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners. Cancer Immunol. Immunother. 59: 1401-1409.
52. Zhu, X., F. Nishimura, K. Sasaki, et al. 2007. Toll-like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med. 5: 10.
53. Eguchi, J., M. Hatano, F. Nishimura, et al. 2006. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 66: 5883-5891.
54. Okano, F., W.J. Storkus, W.H. Chambers, et al. 2002. Identification of a novel HLA-A*0201 restricted cytotoxic T lymphocyte epitope in a human glioma associated antigen, interleukin-13 receptor 2 chain. Clin. Cancer Res. 8: 2851-2855.
55. Hatano, M., J. Eguchi, T. Tatsumi, et al. 2005. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7: 717-722.
56. + cytotoxic T lymphocytes generated against a WT1 peptide analogue. Leukemia Lymphoma 50: 260-269.
57. Nakahara, Y., H. Okamoto, T. Mineta, et al. 2004. Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas. Brain Tumor Pathol. 21: 113-116.
58. Uematsu, M., I. Ohsawa, T. Aokage, et al. 2005. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J. Neurooncol. 72: 231-238.
59. Andersen, M.H., L.O. Pedersen, J.C. Becker, et al. 2001. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61: 869-872.
60. Ciesielski, M., D. Kozbor, C. Castanaro, et al. 2008. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol. Immunother. 57: 1827-1835.
61. Debinski, W. & D.M. Gibo 2000. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol. Med. 6: 440-449.
62. Debinski, W., D.M. Gibo, S.W. Hulet, et al. 1999. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res. 5: 985-990.
63. Wykosky, J., D.M. Gibo, C. Stanton, et al. 2005. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3: 541-551.
64. Yan, H., D.W. Parsons, G. Jin, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360: 765-773.
65. Choi, C., S.K. Ganji, R.J. DeBerardinis, et al. 2012. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18: 624-629.